Compare Baxter International Inc (BAX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Marsh & McLennan Companies, Inc. trades at $181.62 (market cap $85.78B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.6× Baxter International Inc's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.22%). Which is the better fit depends on your goals.
| BAX | MRSH | |
|---|---|---|
Market Cap | $11.26B | $85.78B |
Sector | Health | Financials |
52-Week High | $29.22 | $212.28 |
52-Week Low | $15.80 | $157.32 |
Enterprise Value | $18.93B | $106.62B |
Dividend Yield | 0.92% | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Marsh (MRSH) trades at $181.53, up 1.81% with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations. Revenue grew to $26.98B in 2025 with a 14.26% net margin, while recent dividend increases and strategic acquisitions highlight management's confidence in cash flow generation.
The stock presents a balanced outlook with 33% analyst buy ratings and a $203.67 consensus target offering 12% upside. However, elevated valuation ratios and bearish oscillators suggest near-term consolidation risk. Key catalysts include Q2 2026 earnings and sustained organic growth amid easing insurance pricing headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
